135 related articles for article (PubMed ID: 30535506)
1. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Zhu J; Tao L; Jin L
Mol Med Rep; 2019 Feb; 19(2):1331-1339. PubMed ID: 30535506
[TBL] [Abstract][Full Text] [Related]
2. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
3. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
4. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
5. miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.
Li F; Li H; Li S; Lv B; Shi J; Yan H; Zhang H; He Y
Pharmacogenomics; 2020 Jul; 21(11):771-783. PubMed ID: 32635799
[No Abstract] [Full Text] [Related]
6. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting
Wang Z; Pan L; Yu H; Wang Y
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29592872
[TBL] [Abstract][Full Text] [Related]
7. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
9. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
Tang X; Jiang J; Zhu J; He N; Tan J
Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
Chen JC; Su YH; Chiu CF; Chang YW; Yu YH; Tseng CF; Chen HA; Su JL
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S555-63. PubMed ID: 24723223
[TBL] [Abstract][Full Text] [Related]
11. Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Zhou J; Qu G; Zhang G; Wu Z; Liu J; Yang D; Li J; Chang M; Zeng H; Hu J; Fang T; Song Y; Bai C
J Exp Clin Cancer Res; 2019 Feb; 38(1):96. PubMed ID: 30791926
[TBL] [Abstract][Full Text] [Related]
12. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
13. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract][Full Text] [Related]
14. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
17. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
18. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Zhou YM; Liu J; Sun W
Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
[TBL] [Abstract][Full Text] [Related]
19. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
20. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
